Table 4.
Clinical features of all 18 on-protocol and two off-protocol participants for whom prostate cancer was diagnosed in the first screening round
| Age at diagnosis, years | Diagnostic PSA concentration, ng/mL | Previous PSA test | Family history of prostate cancer | Previous urinary symptoms |
Risk scores |
Biopsy |
Treatment | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer risk* | Gleason score† | T stage† | N stage† | M stage† | Total cores taken | Total cancer cores | |||||||
| On-protocol cancers (PSA >3 ng/mL) | |||||||||||||
| MSH2 non-carrier | 66 | 5·3 | No | No | No | Low | 3+3 | T2a | Nx | M0 | 10 | 1 | Radical prostatectomy |
| MSH2 carrier | 58 | 3·05 | Yes | No | No | Low | 3+3 | T1c | N0 | M0 | 12 | 5 | Active surveillance |
| MSH2 carrier | 57 | 11·05 | Yes | Yes | No | Intermediate | NA | NA | NA | NA | NA | NA | Radical prostatectomy plus hormone therapy |
| MSH2 carrier | 69 | 10·0 | Yes | No | Yes | Intermediate | 4+3 | T2a | NA | NA | 14 | 3 | Non-surgical treatment |
| MSH2 carrier | 60 | 31·1 | No | No | No | High | 4+3 | T3 | NA | NA | NA | NA | Radiotherapy |
| MSH2 carrier | 64 | 89·7 | No | No | No | High | 4+5 | T3b | N1 | M1b | NA | NA | Non-surgical treatment |
| MSH2 carrier | 64 | 20·6 | No | Yes | No | High | 4+5 | T3b | NA | NA | 12 | 5 | Non-surgical treatment |
| MSH2 carrier | 40 | 22·5 | No | No | No | High | 4+3 | T2a | Nx | M0 | NA | NA | Radical prostatectomy |
| MSH2 carrier | 58 | 5·8 | No | No | No | Low | 3+3 | NA | NA | NA | 20 | 5 | Active surveillance |
| MSH2 carrier | 44 | 3·3 | No | No | No | High | 3+3 | T2c | N0 | M0 | 28 | 4 | Active surveillance |
| MSH2 carrier | 61 | 14·0 | No | No | No | Intermediate | 3+4 | T2a | N0 | M0 | 15 | 2 | Non-surgical treatment |
| MSH2 carrier | 66 | 13·0 | Yes | No | No | High | 3+4 | T3b | Nx | Mx | 14 | 5 | Radical prostatectomy |
| MSH2 carrier | 48 | 3·5 | Unknown | No | No | High | 4+3 | T2c | N0 | Mx | 18 | 3 | Radical prostatectomy |
| MSH2 carrier | 65 | 29·0 | No | No | Yes | High | 4+4 | T3a | N0 | Mx | NA | NA | Radical prostatectomy plus hormone therapy |
| MSH6 carrier | 67 | 7·8 | No | No | No | High | 4+4 | T2b | N0 | Mx | 10 | 1 | Active surveillance |
| MSH6 carrier | 55 | 11·1 | No | No | No | High | 3+4 | T2c | N0 | M0 | 13 | 4 | Radical prostatectomy |
| MSH6 carrier | 62 | 4·5 | No | No | No | High | 3+4 | T2c | Nx | M0 | NA | NA | Radical prostatectomy |
| MSH6 carrier | 66 | 3·4 | Yes | No | Yes | Low | 3+3 | NA | NA | NA | 12 | 1 | Active surveillance |
| Off-protocol cancers (PSA ≤3·0 ng/mL) | |||||||||||||
| MSH2 carrier | 49 | 0·85 | No | No | No | High | 5+4 | T3a | N0 | M0 | 12 | 6 | Radical prostatectomy plus hormone and radiotherapy |
| MLH1 non-carrier | 66 | 2·97 | Yes | No | Yes | High | 3+3 | T2c | N0 | M0 | NA | NA | Radical prostatectomy |
NA=not available.
*
Using National Institute for Health and Care Excellence guidelines.
†
Gleason score and TNM stage were taken from the participants' most recent histology data.